"Pentoxifylline in treating symptomatic peripheral arterial disease"@en . "Pentoxifylin v l\u00E9\u010Db\u011B symptomatick\u00E9 ischemick\u00E9 choroby tepen doln\u00EDch kon\u010Detin"@cs . "Pentoxifylin v l\u00E9\u010Db\u011B symptomatick\u00E9 ischemick\u00E9 choroby tepen doln\u00EDch kon\u010Detin" . "1"^^ . "2"^^ . "Klinick\u00E1 farmakologie a farmacie" . . "I" . "Pentoxifylline in treating symptomatic peripheral arterial disease"@en . . . "1212-7973" . . "RIV/00216208:11140/14:10271590!RIV15-MSM-11140___" . . "Peripheral arterial disease (PAD) is an atherothrombotic syndrome in which there is a progressive narrowing of the arteries of the legs. Intermittent claudication is a clinical sign of symptomatic PAD. The development of symptomatic PAD significantly affects the quality of life and, in coincidence with other atherosclerotic manifestations, increases the mortality rate in this group of patients. Our study evaluated the effect of the vasoactive substance pentoxifylline on the claudication interval in symptomatic patients with PAD. Parenteral administration of pentoxifylline infusion therapy in a group of 50 patients with a worsening of claudication symptoms resulted in a statistically significant prolongation of the claudication interval (p < 0.01) and an increased ankle-brachial index (p < 0.001). A positive effect of intravenous pentoxifylline on the indices of the oxidative status and fibrinogen levels (p < 0.05) was seen after a 2-week wash-out period. Similar results have been observed in patients with long-term oral treatment with pentoxifylline. From the data obtained, we consider parenteral administration of pentoxifylline in patients with PAD and a worsening of claudication symptoms to be a reasonable option, given the objectively confirmed effect on claudication pain and the increase in the ankle-brachial index."@en . "Pentoxifylin v l\u00E9\u010Db\u011B symptomatick\u00E9 ischemick\u00E9 choroby tepen doln\u00EDch kon\u010Detin" . . "[0587FFB4D0F7]" . "CZ - \u010Cesk\u00E1 republika" . "11140" . "Hrom\u00E1dka, Milan" . . "Such\u00FD, David" . "Klinick\u00FDm p\u0159\u00EDznakem ischemick\u00E9 choroby doln\u00EDch kon\u010Detin (ICHDK) jsou intermitentn\u00ED klaudikace, kter\u00E9 p\u0159i progresi onemocn\u011Bn\u00ED vedou k v\u00FDrazn\u00E9mu ovlivn\u011Bn\u00ED kvality \u017Eivota a v koincidenci s dal\u0161\u00EDmi aterosklerotick\u00FDmi projevy i ke zv\u00FD\u0161en\u00ED mortality nemocn\u00FDch. V na\u0161\u00ED pr\u00E1ci jsme posuzovali efekt pentoxifylinu na ovlivn\u011Bn\u00ED klaudika\u010Dn\u00EDho intervalu a laboratorn\u00EDch parametr\u016F u pacient\u016F se symptomatickou ICHDK. Vazodilata\u010Dn\u00ED infuzn\u00ED l\u00E9\u010Dba pentoxifylinem v d\u00E1vce 400 mg/den vedla v souboru 50 nemocn\u00FDch se zhor\u0161en\u00EDm symptom\u016F ICHDK ke statisticky v\u00FDznamn\u00E9mu prodlou\u017Een\u00ED klaudika\u010Dn\u00EDho intervalu (p < 0,01) a zv\u00FD\u0161en\u00ED kotn\u00EDkov\u00E9ho tlaku (p < 0,001). Jednor\u00E1zov\u00E9 intraven\u00F3zn\u00ED pod\u00E1n\u00ED 200 mg pentoxifylinu po 2t\u00FDdenn\u00ED wash-out period\u011B vedlo k pozitivn\u00EDmu ovlivn\u011Bn\u00ED ukazatel\u016F oxida\u010Dn\u00EDho stavu a ke sn\u00ED\u017Een\u00ED hladiny fibrinogenu (p < 0,05). Obdobn\u00E9 v\u00FDsledky jsme zaznamenali i po peror\u00E1ln\u00EDm pod\u00E1n\u00ED 400 mg pentoxifylinu u nemocn\u00FDch dlouhodob\u011B l\u00E9\u010Den\u00FDch t\u00EDmto prepar\u00E1tem. Ze z\u00EDskan\u00FDch dat pova\u017Eujeme hospitalizaci s pod\u00E1v\u00E1n\u00EDm vazodilata\u010Dn\u00EDch infuz\u00ED u nemocn\u00FDch se zhor\u0161en\u00EDm klaudika\u010Dn\u00EDch obt\u00ED\u017E\u00ED za \u00FA\u010Delnou pro prok\u00E1zan\u00E9 ovlivn\u011Bn\u00ED klaudika\u010Dn\u00EDch bolest\u00ED na pohybliv\u00E9m chodn\u00EDku a zv\u00FD\u0161en\u00ED kotn\u00EDkov\u00E9ho indexu."@cs . . "4"^^ . . . . . "36078" . "2" . "Pentoxifylin v l\u00E9\u010Db\u011B symptomatick\u00E9 ischemick\u00E9 choroby tepen doln\u00EDch kon\u010Detin"@cs . . "Klinick\u00FDm p\u0159\u00EDznakem ischemick\u00E9 choroby doln\u00EDch kon\u010Detin (ICHDK) jsou intermitentn\u00ED klaudikace, kter\u00E9 p\u0159i progresi onemocn\u011Bn\u00ED vedou k v\u00FDrazn\u00E9mu ovlivn\u011Bn\u00ED kvality \u017Eivota a v koincidenci s dal\u0161\u00EDmi aterosklerotick\u00FDmi projevy i ke zv\u00FD\u0161en\u00ED mortality nemocn\u00FDch. V na\u0161\u00ED pr\u00E1ci jsme posuzovali efekt pentoxifylinu na ovlivn\u011Bn\u00ED klaudika\u010Dn\u00EDho intervalu a laboratorn\u00EDch parametr\u016F u pacient\u016F se symptomatickou ICHDK. Vazodilata\u010Dn\u00ED infuzn\u00ED l\u00E9\u010Dba pentoxifylinem v d\u00E1vce 400 mg/den vedla v souboru 50 nemocn\u00FDch se zhor\u0161en\u00EDm symptom\u016F ICHDK ke statisticky v\u00FDznamn\u00E9mu prodlou\u017Een\u00ED klaudika\u010Dn\u00EDho intervalu (p < 0,01) a zv\u00FD\u0161en\u00ED kotn\u00EDkov\u00E9ho tlaku (p < 0,001). Jednor\u00E1zov\u00E9 intraven\u00F3zn\u00ED pod\u00E1n\u00ED 200 mg pentoxifylinu po 2t\u00FDdenn\u00ED wash-out period\u011B vedlo k pozitivn\u00EDmu ovlivn\u011Bn\u00ED ukazatel\u016F oxida\u010Dn\u00EDho stavu a ke sn\u00ED\u017Een\u00ED hladiny fibrinogenu (p < 0,05). Obdobn\u00E9 v\u00FDsledky jsme zaznamenali i po peror\u00E1ln\u00EDm pod\u00E1n\u00ED 400 mg pentoxifylinu u nemocn\u00FDch dlouhodob\u011B l\u00E9\u010Den\u00FDch t\u00EDmto prepar\u00E1tem. Ze z\u00EDskan\u00FDch dat pova\u017Eujeme hospitalizaci s pod\u00E1v\u00E1n\u00EDm vazodilata\u010Dn\u00EDch infuz\u00ED u nemocn\u00FDch se zhor\u0161en\u00EDm klaudika\u010Dn\u00EDch obt\u00ED\u017E\u00ED za \u00FA\u010Delnou pro prok\u00E1zan\u00E9 ovlivn\u011Bn\u00ED klaudika\u010Dn\u00EDch bolest\u00ED na pohybliv\u00E9m chodn\u00EDku a zv\u00FD\u0161en\u00ED kotn\u00EDkov\u00E9ho indexu." . "disease; arterial; peripheral; symptomatic; treating; Pentoxifylline"@en . . . . "RIV/00216208:11140/14:10271590" . "28" . .